Journal Information
Vol. 48. Issue 10.
Pages 385-386 (October 2012)
Vol. 48. Issue 10.
Pages 385-386 (October 2012)
Letter to the Editor
Full text access
Small-cell Lung Cancer and Elevated CA 19.9 Tumor Marker Levels
Carcinoma microcítico de pulmón y elevación del marcador tumoral CA 19.9
Visits
21525
José María Prieto De Paulaa,
Corresponding author
jmpripaula@yahoo.es

Corresponding author.
, Eduardo Mayor Toranzoa, Laura Gallardo Borgea, Silvia Franco Hidalgob
a Servicio de Medicina Interna, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
b Servicio de Medicina Interna, Complejo Hospitalario de Palencia, Palencia, Spain
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Tables (1)
Table 1. Characteristics of Patients With High CA 19.9.
Full Text
Dear Editor,

The CA 19.9 antigen is a glycoprotein synthesized in several epithelia that is typically high in the serum of patients with pancreatic tumors. Thus, levels above 300U/l have a positive predictive value of about 90%.1 Other tumors (bile duct, gastric, colon, hepatic, ovarian, endometrial, pulmonary, or urothelial) or different benign processes (hepatitis, cirrhosis, cholangitis, cholecystitis, pancreatic pseudocyst, pancreatitis, pulmonary fibrosis, bronchial asthma, asbestosis, bronchiectasis, tuberculosis, renal failure, mucinous cysts, hydronephrosis, Sjögren's syndrome, rheumatoid arthritis, erythematous lupus, dermatopolymyositis, or giant cell arteritis2–4) may also run their course with high serum CA 19.9 levels (in the latter case, with more moderate values).

Increased serum levels of CA 19.9 in lung tumors, especially in adenocarcinomas, are a known fact, although uncommon.5–7 Therefore, we consider it interesting to discuss 4 cases of pulmonary non-small-cell carcinoma treated in our unit within the last 2 years. The notably high CA 19.9, especially in 2 of the patients, made the initial suspected diagnosis lean toward digestive tumor processes.

In the time period, we treated 4 males, all with important smoking histories, non-small-cell lung cancer and CA 19.9 values higher than 300U/l. Mean age was 64.5 (SD, 4.01), and general patient characteristics are shown in Table 1.

Table 1.

Characteristics of Patients With High CA 19.9.

Case  Age/Sex  Symptoms  AST/ALT, UI/la  GGT/FA, UI/lb  CA 19.9, U/lc  CEA, ng/mld  CA-125e  Enolasef  CYFRA 21.1g  SCCh  Pro-GRPi  Diagnosis 
68/M  Deterioration of general condition and weight loss; right hilar mass  92/73  568/392  524.2  3778  327  NO  NO  NO  Small-cell lung cancer with hepatic metastases 
64/M  Deterioration of general condition, weight loss and general pain; right hilar mass  209/173  923/527  >60000  35  57  275  14.4  1.1  13400  Small-cell lung cancer with lung, mediastinal, bone, hepatic and suprarenal affectation 
59/M  Affectation of the general condition and cough; left hilar mass  95/52  2698/324  10599  896  91  NO  NO  NO  Small-cell undifferentiated carcinoma with hepatic and peritoneal metastases 
67/M  Abdominal pain, affectation of the general condition and weight loss; right hilar mass  N/47  190/224  671  59  370  NO  NO  18334  Small-cell lung carcinoma with pleural, hepatic and bone metastases 
a

AST: aspartate-aminotransferase, reference value (rv): 2-38U/l; ALT: alanine-aminotransferase, rv: 2–41U/l.

b

GGT: gamma-glutamyl transpeptidase, rv: 7–50U/l; FA: alkaline phosphatase, rv: 40–129U/l.

c

CA 19.9, rv: 0–37U/ml.

d

CEA: carcinoembryonic antigen, rv: 0–5ng/ml.

e

CA-125, rv: 0–35U/ml.

f

Enolase, rv: 1–20ng/ml.

g

CYFRA 21.1, rv: 0.1–3.3ng/ml.

h

SCC: squamous cell carcinoma antigen, rv: 0–2ng/ml.

i

Pro GRP: pro-gastrin-releasing peptide, rv: 0–63pg/ml.

Except in one of the cases, the clinical presentation included severe deterioration of the patients’ condition, with very striking cholestasis and hepatomegaly. This, together with high CA 19.9 levels (in all 4 patients above 500U/l, and above 10000U/l in 2) meant that the initial suspected diagnosis did not coincide with the definitive diagnosis. In the 4 cases, abdominal computed tomography (CT) ruled out pancreatic masses. Meanwhile, neuron-specific enolase (determined in 3 patients) was clearly high, as was pro-gastrin-releasing peptide (Pro GRP), with values that were 200 times above normal. The poor survival in the 4 patients (just 16 weeks on average) reflected the advanced clinical state at presentation.

Tumor markers are substances that are produced or induced by either a tumor or by the surrounding tissues.8 They have limited specificity and sensitivity, although they are of interest in tumor diagnosis. Their main application resides in follow-up, in the evaluation of treatment efficacy and in prognosis.

Neuron-specific enolase, Pro GRP, squamous cell carcinoma (SCC) antigen, or CYFRA 21.1 are markers that are usually used when given the suspicion for lung cancer (small-cell in the first 2 cases or epidermoid in the remainder). Nevertheless, publications in the medical literature about the management of this entity do not recommend the systematic use of tumor markers due to their very limited efficacy, and they hardly even mention CA 19.9, which is not considered useful in this context.9,10

CA 19.9 is present in the glands of bronchi and bronchioles. It is therefore plausible (although immunohistochemistry techniques are not done) that the origin of their increased level is the neoplastic bronchiolar epithelium,7 regardless of the potential impact of the hepatic metastasis in all the reported cases.

It can thus be deduced that CA 19.9 may present higher levels in small-cell lung cancer, although its determination is not considered clinically useful. This consideration may be useful in order to properly interpret analytic and imaging results in this context.

References
[1]
W. Steimberg.
The clinical utility of CA 19.9 tumor associated antigen.
Am J Gastroenterol, 85 (1990), pp. 350-355
[2]
S. Maestranzi, R. Przemioslo, H. Mitchell, R.A. Sherwood.
The effect of benign and malignant liver disease on the tumour markers CA 19-9 and CEA.
Ann Clin Biochem, 35 (1998), pp. 99-103
[3]
T. Sohda, Y. Iwata, H. Shijo, Y. Egashira, K. Egashira, M. Okumura.
Increased expression of proliferating cell nuclear antigen in autoimmune hepatitis in a patient with raised serum concentration of CA 19-9.
J Clin Pathol, 51 (1998), pp. 167-173
[4]
A. Meyer, I. Kausch, S. Krüger, S. Fetscher, A. Böhle, D. Jocham.
Elevation of CA 19-9 in giant hydronephrosis induced by a renal calculus.
[5]
Y. Rottenberg, B. Nisman, T. Peretz.
Extreme high levels of CA 19.9 associated with adenocarcinoma of the lung.
Isr Med Assoc J, 11 (2009), pp. 116-117
[6]
H. Nagami, T. Nohara, M. Yamauchi, K. Yamada, A. Nakase.
A case of two patients with primary lung cancer secreting CA 19-9.
Nippon Geka Gakkai Zasshi, 89 (1988), pp. 292-296
[7]
M. López-Gómez, M.A. López-Ruz, J.F. Jiménez-Alonso.
Elevación del marcador tumoral CA 19-9 en un adenocarcinoma pulmonar.
Rev Clin Esp, 204 (2004), pp. 290-291
[8]
F. Navarro Expósito, B. Prieto Ríos, M. Martín Angulo, M. Álvarez-Mon Soto.
Indicaciones de solicitud y valor de los marcadores tumorales.
Medicine, 10 (2009), pp. 1854-1858
[9]
R. Molina, J.M. Auge, X. Filella, N. Viñolas, J. Alicarte, J.M. Domingo, et al.
Pro-gastrin-realeasing peptide (Pro GRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Anticancer Res, 25 (2005), pp. 1773-1778
[10]
M. González Barón, J. Espinosa Arranz, J. de la Gándara Porres, G. de Paredes.
Utilidad práctica de los marcadores serológicos en el carcinoma de pulmón.
Med Clin (Barc), 96 (1991), pp. 707-710

Please cite this article as: Prieto De Paula JM, et al. Carcinoma microcítico de pulmón y elevación del marcador tumoral CA 19.9. Arch Bronconeumol. 2012;48:385–6.

Copyright © 2012. SEPAR
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?